secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2026-08-11T20:04:43+00:00
Accession:  0001193125-26-344572
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna Q2: net loss $38.3M ($0.63/share); RMAT for miv-cel in naSPMS; SPS BLA on track for Q4 2026
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $199.4M at June 30, 2026; operating runway into 2028.
- Q2 2026 R&D expenses $24.8M; G&A expenses $14.8M; net loss $38.3M or $0.63 per share.
- FDA granted RMAT designation for miv-cel in non-active secondary progressive MS (naSPMS) based on IIT data from Stanford and UCSF.
- Rolling BLA for miv-cel in stiff person syndrome underway; CMC module submitted; completion targeted Q4 2026 with priority review and potential 2027 launch.
- KYSA-6 Phase 3 gMG enrollment expected complete mid-2027; KYSA-8 12-month and Phase 2 gMG follow-up topline data expected Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526344572/0001193125-26-344572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526344572/kytx-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-344572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer